Success Metrics

Clinical Success Rate

75.0%

Based on 3 completed trials

Completion Rate

75%(3/4)

Active Trials

0(0%)

Results Posted

100%(3 trials)

Terminated

1(25%)

Phase Distribution

Ph phase_3

75%

Ph phase_1

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

1(25.0%)

Phase 3Large-scale testing

3(75.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Terminated(1)

Detailed Status

Completed3

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

75.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (25.0%)

Phase 33 (75.0%)

Trials by Status

terminated125%

completed375%

Recent Activity

0 active trials

Showing 4 of 4

completedphase_3

MK-0524B Lipid Study (MK-0524B-063)

NCT00479882

completedphase_3

Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)

NCT00289900

completedphase_3

Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)

NCT00376584

terminatedphase_1

A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)

NCT01583647

Clinical Trials (4)

Showing 4 of 4 trials

NCT00479882Phase 3

MK-0524B Lipid Study (MK-0524B-063)

Completed

NCT00289900Phase 3

Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)

Completed

NCT00376584Phase 3

Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)

Completed

NCT01583647Phase 1

A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)

Terminated

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4